Stage IV Prostate Cancer AJCC v8 Clinical Trials

56 clinical trials for Stage IV Prostate Cancer AJCC v8 across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer — RECRUITING · PHASE1
• SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma — RECRUITING · PHASE3
• Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients — RECRUITING · PHASE1
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network — RECRUITING
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial — RECRUITING · NA
• Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation — RECRUITING · NA
• Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer — RECRUITING · PHASE2
• Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial — RECRUITING · PHASE2
• Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer — RECRUITING · PHASE2
• Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer — RECRUITING · PHASE2
• Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy — RECRUITING · PHASE2
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer — RECRUITING · PHASE3
• Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring — RECRUITING · PHASE2
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — ACTIVE_NOT_RECRUITING · PHASE2
• M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy — ACTIVE_NOT_RECRUITING · PHASE2
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
• A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer — TERMINATED · PHASE2
• Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study — ACTIVE_NOT_RECRUITING · PHASE2
• Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer — TERMINATED · PHASE2
• A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy — ACTIVE_NOT_RECRUITING · PHASE3
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
• Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) — ACTIVE_NOT_RECRUITING · PHASE2
• Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes — COMPLETED
• Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study — COMPLETED · NA
• Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer — TERMINATED · PHASE1
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate — ACTIVE_NOT_RECRUITING · PHASE1
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones — TERMINATED · PHASE2
• Genetic Testing for Men With Metastatic Prostate Cancer — TERMINATED
• Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer — SUSPENDED · PHASE2
• 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression — TERMINATED · PHASE1
• Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer — WITHDRAWN · PHASE2
• Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer — WITHDRAWN · PHASE1
• Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE2
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer — COMPLETED · PHASE1
• Gallium-68 PSMA-11 PET in Participants With Prostate Cancer — WITHDRAWN · PHASE2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1
• A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer — NOT_YET_RECRUITING · PHASE2
• Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer — TERMINATED · PHASE2

Refine this search